Mechanisms of lipid elevations associated with the treatment of patients with HIV infection

MedGenMed Medscape General Medicine

Volumn 5, Issue 2, 2003, Pages

  Piliero, Peter J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA INTERFERON; AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; ATAZANAVIR; CYTOCHROME P450 3A; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEVINOLIN; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID BINDING PROTEIN 1; RITONAVIR; SAQUINAVIR; SCAVENGER RECEPTOR BI; SIMVASTATIN; UNCLASSIFIED DRUG;

ACCESS TO INFORMATION; ACUTE HEMORRHAGIC PANCREATITIS; ARTICLE; CLINICAL TRIAL; DIET; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CHOICE; DRUG METABOLISM; DYSLIPIDEMIA; EXERCISE; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INFORMATION RETRIEVAL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPODYSTROPHY; LIPOLYSIS; LIVER TOXICITY; LONG TERM CARE; MEDLINE; METABOLIC SYNDROME X; STEROL SYNTHESIS; TREATMENT CONTRAINDICATION;

EID: 25144511573     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Melroe NH, Kopaczewski J, Henry K, Huebsch J. Lipid abnormalities associated with protease inhibitors. J Assoc Nurses AIDS Care. 1999;10:22-30.
3. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
4. Collier AC, Coombs RW, Schoenfeld DA, et al, for the AIDS Clinical Trials Group. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
5. Hammer SM, Squires KE, Hughes MD, et al, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
7. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-47.
8. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
9. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
10. Foody JA. Preventive cardiology. Curr Opin Cardiol. 1999;14:382-391.
11. Veronese L, Rautaureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother. 2000;44:821-826.
12. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
13. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
14. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
16. Dube MP, Sprecher D, Henry WK, et al, for the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis. 2000;31:1216-1224.
17. Rodwell GE, Maurer TA, Berger TG. Fat redistribution in HIV disease. J Am Acad Dermatol. 2000;42:727-730.
18. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
19. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
20. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
21. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000;30 (suppl 2):S135-S142.
22. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475-481.
23. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:441-449.
24. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis. 1999;28:161-162.
25. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000;32:111-123.
26. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.
27. Walmsley S, Bernstein B, King M, et al, for the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
28. Danner SA, Carr A, Leonard JM, et al, for the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-1533.
29. Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol. 1998;46:518-519.
30. Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001;15:725-734.
31. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173.
32. Staels B. Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol. 2001;45:S158-S167.
33. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-1883.
34. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994;264:1471-1474.
35. Zambon A, Schmidt I, Beisiegel U, Brunzell JD. Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. J Lipid Res. 1996;37:2394-2404.
36. Petit JM, Duong M, Florentin E, et al. Down expression of LDL receptor in HIV-infected patients on HAART: qualification by flow cytometry [abstract 661]. Last update 2001. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts /661.htm. Accessed October 4, 2001.
37. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol. 2001;96:2468-2472.
38. Shinohara E, Yamashita S, Kihara S, et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology. 1997;25:1502-1506.
39. Smart EJ, Matveev S, Kencer J, Greenberg RN. Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation [abstract 662]. Last update 2001. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts /662.htm. Accessed September 19, 2001.
40. Geloen A, Roy PE, Bukowiecki LJ. Regression of white adipose tissue in diabetic rats. Am J Physiol. 1989;257:E547-E553.
41. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
42. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol. 2000;20:2625-2629.
43. del Castillo-Olivares A, Gil G. Differential effects of sterol regulatory binding proteins 1 and 2 on sterol 12 alpha-hydroxylase. SREBP-2 suppresses the sterol 12 alpha-hydroxylase promoter. J Biol Chem. 2002;277:6750-6757.
44. Pai JT, Guryev O, Brown MS, Goldstein JL. Differential stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual nuclear sterol regulatory element-binding proteins. J Biol Chem. 1998;273:26138-26148.
45. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum C, Hui DY. HIV protease inhibitor therapy increases hepatic lipoprotein production via stabilization of activated sterol regulatory element-binding protein-1 (SREBP-1) in the nucleus [abstract 659]. Last update 2001. Available at: http://www.retroconference.org/ 2001/abstracts/abstracts/abstracts/659.htm. Accessed October 4, 2001.
46. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397-2406.
47. Juette A, Salzberger B, Franzen C, et al. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors [abstract 656]. Last update 1999. Available at: http://www.retroconference.org/ 99/abstracts/656.htm. Accessed October 1, 2001.
48. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men [abstract 657]. Last update 2001. Available at: http://www.retroconference.org/ 2001/abstracts/abstracts/abstracts/657.htm. Accessed September 19, 2001.
49. Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs. 1998;56 (suppl 1):9-13.
50. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
51. Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001;15:2001-2010.
52. Piliero PJ. Interaction between ritonavir and statins [letter]. Am J Med. 2002;112:510-511.
53. Walli RK, Michl GM, Bogner JR, Geobel FD. Effects of the PPAR-gamma activator troglitazone on protease inhibitor associated peripheral insulin resistance [abstract 673]. Last update 1999. Available at: http://www.retroconference.org/99/abstracts/673.htm. Accessed October 10, 2001.
54. Cahn P, Pantaleo G, Gatell J, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile [abstract]. Program and abstracts of the XIVth World Congress of Cardiology; May 5-9, 2002; Sydney, Australia.
55. Haas DW, Zala C, Schrader S, et al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48) [abstract 42]. Last update 2002. Available at: http://63.126.3.84/2002/ Abstract/13797.htm. Accessed February 12, 2003.
56. Murphy R, Thiry A, Mancini M, Pokrovsky V, Rozenbaum W. Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS AI424-044 [abstract LbPeB9013]. Program and abstracts of the AIDS 2002-XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
57. Parker RA, Wang S, Meyers D, et al. Differentiation of HIV protease inhibitors in models of lipid and glucose metabolism and gene expression in adipocytes and hepatocytes [abstract 100]. Antivir Ther. 2001;6(suppl 4):67.
58. Sension M, Thiry A, Giordano M, for the AI424-034 International Study Team. Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily each with fixed-dose zidovudine plus lamivudine [abstract]. Antiviral Therapy. 2002;7:L26.